Drug treatment for spinal muscular atrophy types II and III-Reference-Cited by-同舟云学术

Drug treatment for spinal muscular atrophy types II and III

Published:2012-04-18 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Wadman Renske I¹,Bosboom Wendy MJ²,van der Pol W Ludo¹,van den Berg Leonard H¹,Wokke John HJ¹,Iannaccone Susan T³,Vrancken Alexander FJE¹

Affiliation:

1. University Medical Center Utrecht; Department of Neurology; Rudolf Magnus Institute for Neuroscience Universiteitsweg 100 Utrecht Netherlands 3584 CG

2. Sint Lucas Andreas Hospital; Department of Neurology; Jan Tooropstraat 164 Amsterdam Netherlands 1061 AE

3. University of Texas Southwestern Medical Center; Department of Pediatrics; 5323 Harry Hines Boulevard Dallas Texas USA 75390

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD006282.pub4/fullpdf

Reference184 articles.

1. Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy;Chen;Neurology,2010

2. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy;Mercuri;Neurology,2007

3. A placebo-controlled trial of gabapentin in spinal muscular atrophy;Miller;Journal of the Neurological Sciences,2001

4. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy;Swoboda;PloS One,2010

5. A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report;Tzeng;American Journal of Physical Medicine & Rehabilitation,2000

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spinal Muscular Atrophy;Pediatric Clinics of North America;2023-10

2. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data;European Journal of Paediatric Neurology;2022-07

3. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice‐switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells;Journal of Neurochemistry;2020-01-08

4. Drug treatment for spinal muscular atrophy types II and III;Cochrane Database of Systematic Reviews;2020-01-06

5. Social participation of adult patients with spinal muscular atrophy: Frequency, restrictions, satisfaction, and correlates;Muscle & Nerve;2018-11-15